Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Mallinckrodt
Accenture
Julphar
Queensland Health
Argus Health
Farmers Insurance
Johnson and Johnson
Federal Trade Commission

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROGLITAZONE

« Back to Dashboard

Clinical Trials for Troglitazone

Trial ID Title Status Sponsor Phase Summary
NCT00003058 Troglitazone in Treating Patients With Liposarcoma Unknown status National Cancer Institute (NCI) Phase 2 RATIONALE: Troglitazone may help liposarcoma cells develop into normal cells. PURPOSE: Phase II trial to study the effectiveness of troglitazone in treating patients with malignant liposarcoma.
NCT00003058 Troglitazone in Treating Patients With Liposarcoma Unknown status Dana-Farber Cancer Institute Phase 2 RATIONALE: Troglitazone may help liposarcoma cells develop into normal cells. PURPOSE: Phase II trial to study the effectiveness of troglitazone in treating patients with malignant liposarcoma.
NCT00116545 TART - Troglitazone Atherosclerosis Regression Trial Completed Parke-Davis Phase 2/Phase 3 The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
NCT00242177 Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability Completed Takeda Pharmaceuticals North America, Inc. Phase 1 The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
NCT00242177 Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability Completed University of Illinois at Chicago Phase 1 The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
NCT00290394 Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients Completed Baskent University Phase 4 The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure–reducing effects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Troglitazone

Condition Name

Condition Name for Troglitazone
Intervention Trials
Diabetes Mellitus, Type 2 4
Diabetes 2
Diabetes Mellitus 2
Impaired Glucose Tolerance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Troglitazone
Intervention Trials
Diabetes Mellitus 9
Diabetes Mellitus, Type 2 8
Glucose Intolerance 2
Fractures, Bone 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Troglitazone

Trials by Country

Trials by Country for Troglitazone
Location Trials
United States 13
India 7
Italy 7
Canada 6
Malaysia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Troglitazone
Location Trials
California 3
Texas 2
Maryland 1
Utah 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Troglitazone

Clinical Trial Phase

Clinical Trial Phase for Troglitazone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Troglitazone
Clinical Trial Phase Trials
Completed 12
Unknown status 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Troglitazone

Sponsor Name

Sponsor Name for Troglitazone
Sponsor Trials
Canadian Network for Observational Drug Effect Studies, CNODES 3
Drug Safety and Effectiveness Network, Canada 3
Canadian Institutes of Health Research (CIHR) 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Troglitazone
Sponsor Trials
Other 18
Industry 7
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Fuji
UBS
Covington
Cerilliant
Federal Trade Commission
Cipla
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.